Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMASGXJ)

Drug Name
AMG 900 Drug Info
Synonyms
AMG-900; AMG 900; 945595-80-2; AMG900; UNII-9R2G075611; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; 9R2G075611; N-(4-((3-(2-aminopyrimidin-4-yl)pyridin-2-yl)oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen- 2-yl)phthalazin-1-amine; IVUGFMLRJOCGAS-UHFFFAOYSA-N
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
24856041
CAS Number
CAS 945595-80-2
TTD Drug ID
DMASGXJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Aurora kinase B (AURKB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT9283 DMQ94CT Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [5]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [7]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
CYC116 DMUMHXT Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
SNS-314 DMAC5F2 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
BI-847325 DMY4B6J Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
R763 DME0CJ9 Haematological malignancy 2B33.Y Phase 1 [12]
GSK1070916 DMXRPT6 Advanced solid tumour 2A00-2F9Z Phase 1 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora kinase A (AURKA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT9283 DMQ94CT Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
MLN8237 DMO8PT9 Solid tumour/cancer 2A00-2F9Z Phase 3 [14]
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [5]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [7]
ENMD-2076 DMJZVPB Acute myeloid leukaemia 2A60 Phase 2 [5]
LY3295668 DM8RJTB Solid tumour/cancer 2A00-2F9Z Phase 1/2 [15]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
MLN8054 DMUANF3 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
CYC116 DMUMHXT Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora kinase C (AURKC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [16]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [7]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
SNS-314 DMAC5F2 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
GSK1070916 DMXRPT6 Advanced solid tumour 2A00-2F9Z Phase 1 [13]
GSK1070916A DMCJUI9 Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
MK-6592 DMB5NOI Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [17]
Indirubin-3'-monoxime DMLRQH0 Discovery agent N.A. Investigative [18]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [19]
6-bromoindirubin-3-oxime DM12WYV Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cellular tumor antigen p53 (TP53)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [20]
Methotrexate DM2TEOL Anterior urethra cancer Approved [21]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [22]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [23]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [24]
Paclitaxel DMLB81S Breast carcinoma Approved [25]
Floxuridine DM04LR2 Colorectal cancer 2B91.Z Approved [26]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [27]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [28]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase 4 (CDK4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [30]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [31]
Selenium DM25CGV N. A. N. A. Approved [32]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [33]
Methotrexate DM2TEOL Anterior urethra cancer Approved [34]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [35]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [36]
Quercetin DM3NC4M Obesity 5B81 Approved [37]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [38]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indomethacin DMSC4A7 Bursitis Approved [40]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [41]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [42]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [43]
Gefitinib DM15F0X Colon adenocarcinoma Approved [44]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [45]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [46]
Selenium DM25CGV N. A. N. A. Approved [47]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [48]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase 2 (CDK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [50]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [51]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [52]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [53]
Selenium DM25CGV N. A. N. A. Approved [32]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [54]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [55]
Methotrexate DM2TEOL Anterior urethra cancer Approved [56]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [35]
Quercetin DM3NC4M Obesity 5B81 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By G1/S-specific cyclin-D3 (CCND3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [50]
Gefitinib DM15F0X Colon adenocarcinoma Approved [44]
Quercetin DM3NC4M Obesity 5B81 Approved [37]
Furazolidone DM3P6V7 Diarrhea ME05.1 Approved [57]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [58]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [59]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [60]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [61]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [62]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [64]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [65]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [66]
Gefitinib DM15F0X Colon adenocarcinoma Approved [67]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [45]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [68]
Etretinate DM2CZFA Keratosis ED56 Approved [69]
Prednisone DM2HG4X Acute asthma CA23 Approved [70]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [54]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [71]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase 4 inhibitor C (CDKN2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [72]
Quercetin DM3NC4M Obesity 5B81 Approved [73]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [38]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [74]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [60]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [75]
Testosterone DM7HUNW Hot flushes GA30 Approved [76]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [76]
Leflunomide DMR8ONJ Arthritis FA20 Approved [77]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [78]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [79]
Gefitinib DM15F0X Colon adenocarcinoma Approved [44]
Prednisone DM2HG4X Acute asthma CA23 Approved [70]
Methotrexate DM2TEOL Anterior urethra cancer Approved [80]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [81]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [82]
Quercetin DM3NC4M Obesity 5B81 Approved [83]
Fluoxetine DM3PD2C Bipolar depression Approved [84]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [85]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [86]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase 6 (CDK6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [31]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [29]
Gefitinib DM15F0X Colon adenocarcinoma Approved [87]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [88]
Methotrexate DM2TEOL Anterior urethra cancer Approved [89]
Quercetin DM3NC4M Obesity 5B81 Approved [90]
Furazolidone DM3P6V7 Diarrhea ME05.1 Approved [57]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [38]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [91]
Panobinostat DM58WKG Chronic graft versus host disease Approved [92]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Modulator [2]
Aurora kinase B (AURKB) TT5LS6T AURKB_HUMAN Modulator [2]
Aurora kinase C (AURKC) TTLYXIT AURKC_HUMAN Modulator [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [3]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Gene/Protein Processing [3]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Gene/Protein Processing [3]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C) OTCLOV90 CDN2C_HUMAN Gene/Protein Processing [3]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Gene/Protein Processing [3]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [3]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Gene/Protein Processing [3]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Gene/Protein Processing [3]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Gene/Protein Processing [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8060).
2 Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
3 AMG900 as novel inhibitor of the translationally controlled tumor protein. Chem Biol Interact. 2021 Jan 25;334:109349. doi: 10.1016/j.cbi.2020.109349. Epub 2020 Nov 28.
4 A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
5 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
6 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
7 Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
9 Clinical pipeline report, company report or official report of Cyclacel.
10 SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
11 doi: 10.1158/1535-7163.TARG-13-B281
12 Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.
13 Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
14 Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
15 Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
16 Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
17 Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009 Aug;14(8):780-93.
18 An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
19 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
20 p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
21 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
22 Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
23 Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
24 Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
25 Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
26 Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
27 Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
28 Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
29 Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
30 p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.
31 In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. Food Chem Toxicol. 2022 Jan;159:112722. doi: 10.1016/j.fct.2021.112722. Epub 2021 Dec 3.
32 Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
33 JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 2007 Apr 10;560(2-3):95-100. doi: 10.1016/j.ejphar.2007.01.020. Epub 2007 Jan 19.
34 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
35 Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
36 A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
37 Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
38 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
39 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
40 The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
41 Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
42 -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
43 Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
44 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
45 BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
46 Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
47 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
48 Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
49 Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
50 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
51 G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
52 Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.
53 Down-regulation and decreased activity of cyclin-dependent kinase 2 in H2O2-induced premature senescence. Int J Biochem Cell Biol. 2003 Feb;35(2):246-54. doi: 10.1016/s1357-2725(02)00129-2.
54 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
55 Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer. 2003 Dec 10;107(5):844-53. doi: 10.1002/ijc.11446.
56 Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
57 Involvement of the p38 MAPK signaling pathway in S-phase cell-cycle arrest induced by Furazolidone in human hepatoma G2 cells. J Appl Toxicol. 2013 Dec;33(12):1500-5. doi: 10.1002/jat.2829. Epub 2012 Oct 30.
58 Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. Diabetologia. 2005 Mar;48(3):586-94. doi: 10.1007/s00125-005-1672-z. Epub 2005 Feb 24.
59 Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res. 2005 Jul 15;65(14):6476-83. doi: 10.1158/0008-5472.CAN-05-0370.
60 Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
61 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
62 DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
63 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
64 Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
65 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
66 Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
67 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
68 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
69 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
70 Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
71 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
72 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
73 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
74 Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
75 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
76 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
77 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
78 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
79 Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
80 Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
81 Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
82 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
83 Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
84 Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
85 Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
86 Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
87 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
88 Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
89 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
90 Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
91 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
92 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.